These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22842446)

  • 21. Botulinum toxin type A treatment for contouring of the lower face.
    Park MY; Ahn KY; Jung DS
    Dermatol Surg; 2003 May; 29(5):477-83; discussion 483. PubMed ID: 12752514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin type A in the management of masseter muscle hypertrophy.
    Castro WH; Gomez RS; Da Silva Oliveira J; Moura MD; Gomez RS
    J Oral Maxillofac Surg; 2005 Jan; 63(1):20-4. PubMed ID: 15635552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Masseteric hypertrophy: considerations regarding treatment planning decisions and introduction of a novel surgical technique.
    Pary A; Pary K
    J Oral Maxillofac Surg; 2011 Mar; 69(3):944-9. PubMed ID: 21195532
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report.
    Mandel L; Tharakan M
    J Oral Maxillofac Surg; 1999 Aug; 57(8):1017-9. PubMed ID: 10437733
    [No Abstract]   [Full Text] [Related]  

  • 25. Exploring botulinum toxin's impact on masseter hypertrophy: a randomized, triple-blinded clinical trial.
    de Souza Nobre BB; Rezende L; Barbosa Câmara-Souza M; Sanchez-Ayala A; Blass R; Carbone AC; Manso AC; Ernberg M; Christidis N; De la Torre Canales G
    Sci Rep; 2024 Jun; 14(1):14522. PubMed ID: 38914688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary: The effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Ahn KY
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2167. PubMed ID: 21244566
    [No Abstract]   [Full Text] [Related]  

  • 27. The treatment of masseter hypertrophy with botulinum toxin type A.
    Al-Ahmad HT; Al-Qudah MA
    Saudi Med J; 2006 Mar; 27(3):397-400. PubMed ID: 16532107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Shim WH; Yoon SH; Park JH; Choi YC; Kim ST
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2161-6. PubMed ID: 21134047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of unilateral idiopathic masseter muscle hypertrophy with botulinum toxin type A.
    Nilesh K; Dharamsi R; Patil P; Mate P
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33462041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.
    Baş B; Ozan B; Muğlali M; Celebi N
    Med Oral Patol Oral Cir Bucal; 2010 Jul; 15(4):e649-52. PubMed ID: 20173718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasound-Guided Botulinum Neurotoxin Injection for Masseter Hypertrophy Based on the Structural Pattern of Deep Inferior Tendon and Masseteric Contraction.
    Wang YH; Chang SL; Hu S; Huang YL
    Plast Reconstr Surg; 2022 Jul; 150(1):240e-242e. PubMed ID: 35767638
    [No Abstract]   [Full Text] [Related]  

  • 32. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy.
    Bae JH; Choi DY; Lee JG; Seo KK; Tansatit T; Kim HJ
    Dermatol Surg; 2014 Dec; 40(12):1334-9. PubMed ID: 25393348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RimabotulinumtoxinB versus OnabotulinumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study.
    Lee DH; Jin SP; Cho S; Feneran A; Youn CS; Won CH; Park GH; Kim BW; An J; Chang SE; Lee MW
    Dermatology; 2013; 226(3):227-32. PubMed ID: 23774030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of a Novel Botulinum Toxin A for Masseter Reduction: A Randomized, Double-Blind, Placebo-Controlled, Optimal Dose-Finding Study.
    Hong JY; Jeong GJ; Kwon TR; Kim JH; Li K; Kim BJ
    Dermatol Surg; 2021 Jan; 47(1):e5-e9. PubMed ID: 33347002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin type A injections for masticatory muscles hypertrophy: A systematic review.
    Rauso R; Lo Giudice G; Tartaro G; Zerbinati N; Nicoletti GF; Fragola R
    J Craniomaxillofac Surg; 2022 Jan; 50(1):7-18. PubMed ID: 34620536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anatomical Considerations When Treating Compensatory Hypertrophy of the Upper Part of the Masseter after Long-Term Botulinum Neurotoxin Type A Injections.
    Lee KL; Cho HJ; Bae H; Park HJ; Park MS; Kim HJ
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32235784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement.
    Kim HJ; Yum KW; Lee SS; Heo MS; Seo K
    Dermatol Surg; 2003 May; 29(5):484-9. PubMed ID: 12752515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of unilateral masseter hypertrophy with botulinum toxin in two cases.
    Işeri M; Işeri PK
    Kulak Burun Bogaz Ihtis Derg; 2004; 12(3-4):99-102. PubMed ID: 16010109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type a injection.
    Wei J; Xu H; Dong J; Li Q; Dai C
    Dermatol Surg; 2015 Jan; 41 Suppl 1():S101-9. PubMed ID: 25548838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache.
    Pihut M; Ferendiuk E; Szewczyk M; Kasprzyk K; Wieckiewicz M
    J Headache Pain; 2016; 17():29. PubMed ID: 27011213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.